CN107432478A - 一种复合亚麻籽油微囊粉及其制备方法 - Google Patents
一种复合亚麻籽油微囊粉及其制备方法 Download PDFInfo
- Publication number
- CN107432478A CN107432478A CN201710627454.5A CN201710627454A CN107432478A CN 107432478 A CN107432478 A CN 107432478A CN 201710627454 A CN201710627454 A CN 201710627454A CN 107432478 A CN107432478 A CN 107432478A
- Authority
- CN
- China
- Prior art keywords
- parts
- vitamin
- linseed oil
- acid
- microcapsule powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003094 microcapsule Substances 0.000 title claims abstract description 33
- 239000000843 powder Substances 0.000 title claims abstract description 32
- 235000021388 linseed oil Nutrition 0.000 title claims abstract description 31
- 239000000944 linseed oil Substances 0.000 title claims abstract description 31
- 150000001875 compounds Chemical class 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 30
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 30
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 28
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 28
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims abstract description 23
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 22
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229940088594 vitamin Drugs 0.000 claims abstract description 22
- 229930003231 vitamin Natural products 0.000 claims abstract description 22
- 235000013343 vitamin Nutrition 0.000 claims abstract description 22
- 239000011782 vitamin Substances 0.000 claims abstract description 22
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 22
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229960003080 taurine Drugs 0.000 claims abstract description 15
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 14
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 14
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 14
- 239000011575 calcium Substances 0.000 claims abstract description 14
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 14
- 235000001465 calcium Nutrition 0.000 claims abstract description 14
- 229960000304 folic acid Drugs 0.000 claims abstract description 14
- 235000019152 folic acid Nutrition 0.000 claims abstract description 14
- 239000011724 folic acid Substances 0.000 claims abstract description 14
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 14
- 239000011718 vitamin C Substances 0.000 claims abstract description 14
- 229960003495 thiamine Drugs 0.000 claims abstract description 13
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims abstract description 13
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229930003451 Vitamin B1 Natural products 0.000 claims abstract description 12
- 235000010374 vitamin B1 Nutrition 0.000 claims abstract description 12
- 239000011691 vitamin B1 Substances 0.000 claims abstract description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims abstract description 11
- 239000004471 Glycine Substances 0.000 claims abstract description 11
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 11
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 11
- 229920001100 Polydextrose Polymers 0.000 claims abstract description 11
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 11
- 229940055726 pantothenic acid Drugs 0.000 claims abstract description 11
- 235000019161 pantothenic acid Nutrition 0.000 claims abstract description 11
- 239000011713 pantothenic acid Substances 0.000 claims abstract description 11
- 239000001259 polydextrose Substances 0.000 claims abstract description 11
- 229940035035 polydextrose Drugs 0.000 claims abstract description 11
- 235000013856 polydextrose Nutrition 0.000 claims abstract description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 10
- 239000008103 glucose Substances 0.000 claims abstract description 10
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000007968 orange flavor Substances 0.000 claims abstract description 10
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000004376 Sucralose Substances 0.000 claims abstract description 9
- 229960003966 nicotinamide Drugs 0.000 claims abstract description 9
- 235000005152 nicotinamide Nutrition 0.000 claims abstract description 9
- 239000011570 nicotinamide Substances 0.000 claims abstract description 9
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims abstract description 9
- 235000019408 sucralose Nutrition 0.000 claims abstract description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 7
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 7
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 6
- 229960002477 riboflavin Drugs 0.000 claims description 6
- 229930003471 Vitamin B2 Natural products 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 235000019164 vitamin B2 Nutrition 0.000 claims description 5
- 239000011716 vitamin B2 Substances 0.000 claims description 5
- 229930003427 Vitamin E Natural products 0.000 claims description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 3
- 235000019165 vitamin E Nutrition 0.000 claims description 3
- 239000011709 vitamin E Substances 0.000 claims description 3
- 229940046009 vitamin E Drugs 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 238000001291 vacuum drying Methods 0.000 claims 1
- 239000000052 vinegar Substances 0.000 claims 1
- 235000021419 vinegar Nutrition 0.000 claims 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 abstract description 20
- 235000020661 alpha-linolenic acid Nutrition 0.000 abstract description 10
- 229960004488 linolenic acid Drugs 0.000 abstract description 10
- 239000000203 mixture Substances 0.000 abstract description 6
- 239000000047 product Substances 0.000 abstract description 5
- 238000005516 engineering process Methods 0.000 abstract description 4
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 239000013589 supplement Substances 0.000 abstract description 3
- 241000196324 Embryophyta Species 0.000 abstract description 2
- 239000002131 composite material Substances 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 229960005069 calcium Drugs 0.000 abstract 1
- 235000015097 nutrients Nutrition 0.000 abstract 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 10
- 210000004381 amniotic fluid Anatomy 0.000 description 9
- 210000003754 fetus Anatomy 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 235000013336 milk Nutrition 0.000 description 6
- 239000008267 milk Substances 0.000 description 6
- 210000004080 milk Anatomy 0.000 description 6
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 229940011671 vitamin b6 Drugs 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 210000001525 retina Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 235000019158 vitamin B6 Nutrition 0.000 description 4
- 239000011726 vitamin B6 Substances 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 235000004431 Linum usitatissimum Nutrition 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 235000019504 cigarettes Nutrition 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 235000019155 vitamin A Nutrition 0.000 description 3
- 239000011719 vitamin A Substances 0.000 description 3
- 229940045997 vitamin a Drugs 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000005232 Glossitis Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 240000006240 Linum usitatissimum Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- -1 amide compound Chemical class 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 210000003792 cranial nerve Anatomy 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 235000004426 flaxseed Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003780 keratinization Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 235000020944 retinol Nutrition 0.000 description 2
- 239000011607 retinol Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 235000015961 tonic Nutrition 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- GDSOZVZXVXTJMI-SNAWJCMRSA-N (e)-1-methylbut-1-ene-1,2,4-tricarboxylic acid Chemical compound OC(=O)C(/C)=C(C(O)=O)\CCC(O)=O GDSOZVZXVXTJMI-SNAWJCMRSA-N 0.000 description 1
- BOKGTLAJQHTOKE-UHFFFAOYSA-N 1,5-dihydroxynaphthalene Chemical compound C1=CC=C2C(O)=CC=CC2=C1O BOKGTLAJQHTOKE-UHFFFAOYSA-N 0.000 description 1
- ADVPTQAUNPRNPO-REOHCLBHSA-N 3-sulfino-L-alanine Chemical compound OC(=O)[C@@H](N)C[S@@](O)=O ADVPTQAUNPRNPO-REOHCLBHSA-N 0.000 description 1
- 206010000242 Abortion threatened Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003671 Atrioventricular Block Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 208000001362 Fetal Growth Retardation Diseases 0.000 description 1
- 206010070531 Foetal growth restriction Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 208000008899 Habitual abortion Diseases 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 241000208202 Linaceae Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N Retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- 241000235342 Saccharomycetes Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 206010040639 Sick sinus syndrome Diseases 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 208000005985 Threatened Abortion Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 229930003571 Vitamin B5 Natural products 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- ADVPTQAUNPRNPO-UHFFFAOYSA-N alpha-amino-beta-sulfino-propionic acid Natural products OC(=O)C(N)CS(O)=O ADVPTQAUNPRNPO-UHFFFAOYSA-N 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 208000030941 fetal growth restriction Diseases 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000005709 nerve cell growth Effects 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 235000020945 retinal Nutrition 0.000 description 1
- 239000011604 retinal Substances 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
- A23L29/35—Degradation products of starch, e.g. hydrolysates, dextrins; Enzymatically modified starches
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明公开了一种复合亚麻籽油微囊粉，由下列重量份的组分配比而成：冷水可分散型亚麻籽油微囊粉4000份、维生素A醋酸酯0.4份、维生素B1 0.4、维生素B2 0.4份、维生素B6 0.4份、维生素C 16份、维生素E醋酸酯4份、牛磺酸6份、泛酸1份、烟酰胺3份、叶酸0.08份、甘氨酸钙20份、磷脂20份、聚葡萄糖400份、葡萄糖800份、麦芽糊精800份、三氯蔗糖10份、甜橙香精100份、柠檬酸80份。本发明采用微囊技术，使亚麻籽油易于溶解；采用复合植物配方，口感更好，更易于人体吸收；并且各成分之间协同增效，产品不仅富含α‑亚麻酸，同时能够补充钙质、维生素、叶酸等成分，具有抗氧化性，更利于人体补充营养。
Description
1、技术领域
本发明涉及一种复合亚麻籽油微囊粉及其制备方法。
2、背景技术
α-亚麻酸及其衍生的长链多不饱和脂肪酸是所有细胞膜和线粒体膜的重要成分，膜磷脂中脂肪酸的组成成分直接影响膜的功能，如酶的催化反应、受体活性、跨膜运转、代谢率等。
细胞膜中ω-3不饱和脂肪酸含量升高时，膜的流动性和可塑性加强。膜的流动性与葡萄糖转运存在着正相关，可增加胰岛素的调节葡萄糖代谢的敏感性，有利于提高糖耐量纠正胰岛素抵抗；细胞膜中脂肪酸的饱和度升高可导致代谢率的下降，易肥胖和体力上的疲劳。而膜的可塑性在对抗动脉硬化、恢复血管弹性方面有重要的作用。
ω-3多不饱和脂肪酸(ω-3PUFA)在神经系统中的结构性作用更是不可缺少的。在胎儿和婴儿时期ω-3PUFA的不足可导致大脑、神经和视网膜的发育不全，对智力和视力的发育产生消极的影响，成人ω-3PUFA的不足亦易产生精神和视力上的疲劳。一般认为，ω-3PUFA在大脑、神经和视网膜中的作用在于它能提供一个高度流动性的膜环境。
α-亚麻酸对人体有非常高的安全性，在小鼠的急慢性毒理实验中，以1.5g/d·kg灌胃90天，未见有任何的毒性反应。但α—亚麻酸在体内有广泛的生理活性，所以在服用时应该注意一些可能的生理反应以及在配伍某些药物时应该注意的一些问题。
α-亚麻酸可以抑制血小板的聚集，延长出、凝血时间，故有严重出血倾向患者(如血友病、血小板低、贫血等)以及在配伍阿斯匹林等抗血小板药使用时应监测凝血功能。
α-亚麻酸及其代谢物DHA是大脑的营养物质，使用后可使大脑的活力增强，耗氧量增加，如果原先有脑供血不足，可能会出现头晕的症状，服用初期减量即可消除不适。
尽管亚麻籽油有很多种保健功能，但在其储藏过程中，会发生的一些化学变化，使其营养功效降低。为了更好的利用α-亚麻酸，我们采取微囊粉的加工工艺，既避免了无法接受的特殊气味，又能防止其在储存过程中营养成分的损失。
3、发明内容
本发明提供一种复合亚麻籽油微囊粉，主要成份易被人体吸收，纯度高、游离态，作用快。
本发明还提供了一种上述复合亚麻籽油微囊粉的制备方法。
为实现上述目的，本发明采用下述技术方案：
一种复合亚麻籽油微囊粉，由下列重量份的组分配比而成：冷水可分散型亚麻籽油微囊粉1000～6000份、维生素A醋酸酯0.1～1份、维生素B1 0.1～1、维生素B2 0.1～1份、维生素B6 0.1～1份、维生素C 10～50份、维生素E醋酸酯1～10份、牛磺酸1～20份、泛酸0.1～2份、烟酰胺1～10份、叶酸0.01～0.1份、甘氨酸钙10～500份、磷脂10～500份、聚葡萄糖300～1000份、葡萄糖500-3000份、麦芽糊精500～3000份、三氯蔗糖1～15份、甜橙香精10-300份、柠檬酸50～200份。
优选的，由下列重量份的组分配比而成：
冷水可分散型亚麻籽油微囊粉3000～5000份、维生素A醋酸酯0.3～0.5份、维生素B1 0.3～0.5、维生素B2 0.3～0.5份、维生素B6 0.3～0.5份、维生素C 10～20份、维生素E醋酸酯1～5份、牛磺酸1～10份、泛酸0.5～2份、烟酰胺1～5份、叶酸0.05～0.1份、甘氨酸钙10～100份、磷脂10～100份、聚葡萄糖300～500份、葡萄糖500-1000份、麦芽糊精500～1000份、三氯蔗糖5～15份、甜橙香精50-200份、柠檬酸50～100份。
更为优选的，由下列重量份的组分配比而成：
冷水可分散型亚麻籽油微囊粉4000份、维生素A醋酸酯0.4份、维生素B1 0.4、维生素B2 0.4份、维生素B6 0.4份、维生素C 16份、维生素E醋酸酯4份、牛磺酸6份、泛酸1份、烟酰胺3份、叶酸0.08份、甘氨酸钙20份、磷脂20份、聚葡萄糖400份、葡萄糖800份、麦芽糊精800份、三氯蔗糖10份、甜橙香精100份、柠檬酸80份。
一种复合亚麻籽油微囊粉的制备方法是，将上述原料真空干燥、粉碎、混合均匀，即得。
其中，α-亚麻酸是构成人体细胞的核心物质，它能在多种酶的作用下，在肝脏代谢为DHA和EPA。DHA和EPA是脑、视网膜等细胞膜的重要成分，都选择性的渗入大脑皮质、视网膜、睾丸、精子等重要器官中，参与构成乙醇胺磷脂和神经磷脂。α-亚麻酸能够促进胎儿视网膜的发育，预防胎儿畸形和细胞突变，改善侧脑室增宽、促进胎儿眼脑神经发育，以及改善胎儿宫内发育迟缓，促进胎儿身体发育；改善孕妇羊水异常、减轻妊娠反应，减少妊娠纹，促进产后体形恢复；预防妊娠性糖尿病、抑郁症、便秘等。
维生素A又称视黄醇(其醛衍生物视黄醛)或抗干眼病因子，是一个具有脂环的不饱和一元醇，包括动物性食物来源的维生素A1、A2两种，是一类具有视黄醇生物活性的物质。维生素A可参与糖蛋白的合成，这对于上皮的正常形成、发育与维持十分重要。当维生素A不足或缺乏时，可导致糖蛋白合成中间体的异常，低分子量的多糖—脂的堆积，引起上皮基底层增生变厚，细胞分裂加快、张力原纤维合成增多，表面层发生细胞变扁、不规则、干燥等变化。鼻、咽、喉和其他呼吸道、胃肠和泌尿生殖系内膜角质化，削弱了防止细菌侵袭的天然屏障(结构)，而易于感染。在儿童，极易合并发生呼吸道感染及腹泻。有的肾结石也与泌尿道角质化有关。过量摄入维生素A，对上皮感染的抵抗力并不随剂量而增高。
维生素B1又称硫胺素或抗神经炎维生素或抗脚气病维生素，为白色晶体，在有氧化剂存在时容易被氧化产生脱氢硫胺素，后者在有紫外光照射时呈现蓝色荧光。维生素B1可以预防婴儿脚气病，婴儿脚气病的最主要表现并不在“脚”，而是全身各脏器都会受累。脚气病出现的症状有轻有重，多数患儿是轻型。但是，如果得不到及时治疗，病情会继续发展，严重时可危及生命。患有脚气病的孩子，常有轻度腹泻、声音嘶哑、烦躁、夜间啼哭、吃奶无力、心跳快，甚至嗜睡、昏迷、抽筋等症状，在其脚部略有浮肿，用手指压迫时，即出现一个凹陷，压力解除后，此凹陷还不能立即消失。维生素B1还可以促进婴儿成长，帮助消化，特别是碳水化合物的消化；改善精神状况；维持神经组织、肌肉、心脏活动的正常；减轻晕机、晕船；可缓解有关牙科手术后的痛；有助于对带状疱疹的治疗。
维生素B2又叫核黄素，微溶于水，在中性或酸性溶液中加热是稳定的。维生素B2在生长代谢中，具有非常重要的作用。当身体缺乏它时，皮肤黏膜就容易发生炎症。表现为口角发生乳白色糜烂、裂口和张口出血，伴疼痛和灼热感等痛苦。久之还会形成溃疡，受细菌感染，如果不及时治疗，便有可能发生喉咙疼、干涩难受、体温升高等不适；同时，还会引起其他部位的皮肤黏膜发生病变，如舌炎、口腔炎、眼结膜炎、脂溢性皮炎、阴囊炎等。维生素B2缺乏较为普遍。小孩由于生长发育快，代谢旺盛，小孩更易缺乏维生素B2，长期缺乏会导致小孩生长迟缓，轻中度缺铁性贫血。
维生素B6又称吡哆素，是一种水溶性维生素，为无色晶体，易溶于水及乙醇，在酸液中稳定，在碱液中易破坏，遇光或碱易破坏，不耐高温。维生素B6在酵母菌、肝脏、谷粒、肉、鱼、蛋、豆类及花生中含量较多。维生素B6为人体内某些辅酶的组成成分，参与多种代谢反应，尤其是和氨基酸代谢有密切关系。临床上应用维生素B6制剂防治妊娠呕吐和放射病呕吐。
维生素C又称L-抗坏血酸，是高等灵长类动物与其他少数生物的必需营养素。抗坏血酸在大多的生物体可借由新陈代谢制造出来，但是人类是最显著的例外。最广为人知的是缺乏维生素C会造成坏血病。在生物体内，维生素C是一种抗氧化剂，保护身体免于自由基的威胁，维生素C同时也是一种辅酶。
维生素E又名生育酚。主要用于抗衰老、预防习惯性流产、先兆流产、绝经期综合征等。也可用于肌萎缩、肌营养不良、肝炎、肝硬化、冠心病的辅助治疗。
泛酸指维生素b5。维生素B5具有制造抗体的功能,在维护头发、皮肤及血液健康方面亦扮演着重要角色。
烟酰胺又称尼克酰胺，是烟酸的酰胺化合物。为白色的结晶性粉末；无臭或几乎无臭，味苦；略有引湿性。在水或乙醇中易溶，在甘油中溶解。临床上主要用于防治糙皮并口炎、舌炎，病态窦房结综合征，房室传导阻滞等问题。
叶酸也叫维生素B9，是一种水溶性维生素。中美预防神经管畸形合作项目于1990年启动，经过中美科学家对追踪观察25万例新婚妇女及其妊娠结局验证，准妈妈在备孕期间就服用0.4毫克叶酸，在神经管畸形高发区有85％预防率，在神经管畸形低发区有41％的预防率，此项科技成果被全球50多个国家广泛应用及借鉴。
麦芽糊精易被人体吸收，使产品体积膨胀、不易结块、速溶、冲调性好，提高营养比价。
聚葡萄糖作为增稠剂，使产品形成必要的体积，可提高食产品油质状口感性，具有低冰点，并且不会导致龋齿，可减低食品中糖，脂肪及淀粉用量，具有低热量。
牛磺酸，在脑内的含量丰富、分布广泛，能明显促进神经系统的生长发育和细胞增殖、分化，且呈剂量依赖性，在脑神经细胞发育过程中起重要作用。研究表明：早产儿脑中的牛磺酸含量明显低于足月儿，这是因为早产儿体内的半胱氨酸亚磺酸脱氢酶(CSAD)尚未发育成熟，合成牛磺酸不足以满足机体的需要，需由母乳补充；牛磺酸与幼儿、胎儿的中枢神经及视网膜等的发育有密切的关系；牛磺酸有维护许多细胞，特别是血细胞抗氧化活性，使组织免受氧化基与自由基的损伤。
甘氨酸钙，属于新型补钙剂，比其它补钙剂更易被人体吸收。
本发明的有益效果是，
1.采用微囊技术，改善了功能活性物质的稳定性和水溶性，使亚麻籽中提取的亚
麻籽油更好保存。
2.采用复合植物配方，清新奶香，口感更好，更易于人体吸收；在加工过程中，进行一定的成分配比的改良，同时各成分之间协同增效，产品不仅富含α-亚麻酸，同时能够补充钙质、叶酸等成分，具有抗氧化性，更利于人体对营养的吸收，可以制成各种口味，适应于各种人群。
4、具体实施方式
实施例1：一种复合亚麻籽油微囊粉，由下列重量份的组分配比而成：
冷水可分散型亚麻籽油微囊粉4000份、维生素A醋酸酯0.4份、维生素B1 0.4、维生素B2 0.4份、维生素B6 0.4份、维生素C 16份、维生素E醋酸酯4份、牛磺酸6份、泛酸1份、烟酰胺3份、叶酸0.08份、甘氨酸钙20份、磷脂20份、聚葡萄糖400份、葡萄糖800份、麦芽糊精800份、三氯蔗糖10份、甜橙香精100份、柠檬酸80份，将上述原料真空干燥、粉碎、混合均匀，即得。
实施例2：一种复合亚麻籽油微囊粉，由下列重量g的组分配比而成：
冷水可分散型亚麻籽油微囊粉3000份、维生素A醋酸酯0.3份、维生素B1 0.3、维生素B2 0.3份、维生素B6 0.3份、维生素C 10份、维生素E醋酸酯1份、牛磺酸1份、泛酸0.5份、烟酰胺1份、叶酸0.05份、甘氨酸钙10份、磷脂10份、聚葡萄糖300份、葡萄糖500份、麦芽糊精500份、三氯蔗糖5份、甜橙香精50份、柠檬酸50份，将上述原料真空干燥、粉碎、混合均匀，即得。
实施例3：一种复合亚麻籽油微囊粉，由下列重量g的组分配比而成：
冷水可分散型亚麻籽油微囊粉5000份、维生素A醋酸酯0.5份、维生素B1 0.5、维生素B2 0.5份、维生素B6 0.5份、维生素C 20份、维生素E醋酸酯5份、牛磺酸10份、泛酸2份、烟酰胺5份、叶酸0.1份、甘氨酸钙100份、磷脂100份、聚葡萄糖500份、葡萄糖1000份、麦芽糊精1000份、三氯蔗糖15份、甜橙香精200份、柠檬酸100份，将上述原料真空干燥、粉碎、混合均匀，即得。
将实施例1-3所得产品依次编号组1、组2、组3，进行相关理化指标和卫生指标的检测，检测结果如表1所示，均符合相关指标要求。
表1组1--组3理化指标检测结果
*：过100目筛。
临床资料：
1.李某，30岁，怀孕35周，羊水指数9cm，胎儿左肾肾盂分离约0.6cm，右肾肾盂分离约0.8cm，服用实施例2的复合亚麻籽油微囊粉，早晚各10g，饭后牛奶送服，服用15天后，羊水指数为12cm，胎儿两侧肾盂分离消失。
2.曹某，28岁，怀孕37周，羊水指数为8.3cm，服用本发明实施例1的复合亚麻籽油微囊粉，早晚各10g，饭后牛奶送服，服用10天后，羊水指数为9.5cm，上升了1.2cm。
3.田某，25岁，怀孕30周，孕检发现胎儿偏小一周，服用本发明实施例3的复合亚麻籽油微囊粉，早晚各10g，饭后牛奶送服，服用28天后，胎儿右侧脑室宽降为10mm，为正常状态，同时胎儿恢复正常孕周大。
4.吴某，32岁，怀孕37周，羊水指数8.2cm，服用本发明实施例2的复合亚麻籽油微囊粉，早晚各10g，饭后牛奶送服，两周后，羊水指数9.7cm，继续服用两周后，羊水正常。
5.董某，27岁，怀孕33周，羊水指数24.2cm，服用本发明实施例3的复合亚麻籽油微囊粉，早晚各5g，饭后豆浆送服，服用1周后，羊水指数20.55cm，继续服用3周后，达到正常值。
上述虽然对本发明的具体实施方式进行了描述，但并非对本发明保护范围的限制。
Claims (4)
1.一种复合亚麻籽油微囊粉，其特征是，由下列重量份的组分配比而成：
冷水可分散型亚麻籽油微囊粉1000～6000份、维生素A醋酸酯0.1～1份、维生素B1 0.1～1、维生素B2 0.1～1份、维生素B6 0.1～1份、维生素C 10～50份、维生素E醋酸酯1～10份、牛磺酸1～20份、泛酸0.1～2份、烟酰胺1～10份、叶酸0.01～0.1份、甘氨酸钙10～500份、磷脂10～500份、聚葡萄糖300～1000份、葡萄糖500-3000份、麦芽糊精500～3000份、三氯蔗糖1～15份、甜橙香精10-300份、柠檬酸50～200份。
2.如权利要求1所述的一种复合亚麻籽油微囊粉，其特征是，由下列重量份的组分配比而成：
冷水可分散型亚麻籽油微囊粉3000～5000份、维生素A醋酸酯0.3～0.5份、维生素B10.3～0.5、维生素B2 0.3～0.5份、维生素B6 0.3～0.5份、维生素C 10～20份、维生素E醋酸酯1～5份、牛磺酸1～10份、泛酸0.5～2份、烟酰胺1～5份、叶酸0.05～0.1份、甘氨酸钙10～100份、磷脂10～100份、聚葡萄糖300～500份、葡萄糖500-1000份、麦芽糊精500～1000份、三氯蔗糖5～15份、甜橙香精50-200份、柠檬酸50～100份。
3.如权利要求1所述的一种复合亚麻籽油微囊粉，其特征是，由下列重量份的组分配比而成：
冷水可分散型亚麻籽油微囊粉4000份、维生素A醋酸酯0.4份、维生素B1 0.4、维生素B20.4份、维生素B6 0.4份、维生素C 16份、维生素E醋酸酯4份、牛磺酸6份、泛酸1份、烟酰胺3份、叶酸0.08份、甘氨酸钙20份、磷脂20份、聚葡萄糖400份、葡萄糖800份、麦芽糊精800份、三氯蔗糖10份、甜橙香精100份、柠檬酸80份。
4.如权利要求1-3任一项所述的复合亚麻籽油微囊粉的制备方法，其特征是，将上述原料真空干燥、粉碎、混合均匀，即得。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710627454.5A CN107432478A (zh) | 2017-07-28 | 2017-07-28 | 一种复合亚麻籽油微囊粉及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710627454.5A CN107432478A (zh) | 2017-07-28 | 2017-07-28 | 一种复合亚麻籽油微囊粉及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107432478A true CN107432478A (zh) | 2017-12-05 |
Family
ID=60459736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710627454.5A Pending CN107432478A (zh) | 2017-07-28 | 2017-07-28 | 一种复合亚麻籽油微囊粉及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107432478A (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108477622A (zh) * | 2018-04-16 | 2018-09-04 | 赵成群 | 一种婴幼儿全功能营养组合物 |
| CN108968072A (zh) * | 2018-10-13 | 2018-12-11 | 王井中 | 亚麻酸微囊粉及其制备方法和使用方法 |
| CN115252675A (zh) * | 2022-05-23 | 2022-11-01 | 南京联智医药科技有限公司 | 犬用美毛护肤软咀嚼片剂及其制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105011153A (zh) * | 2015-06-19 | 2015-11-04 | 北京元莱健康管理有限公司 | 一种促进儿童眼脑发育缓解视疲劳的组合物及其制备方法 |
| CN106617075A (zh) * | 2017-01-18 | 2017-05-10 | 济南善恩医药科技有限公司 | 一种复合亚麻籽油微囊粉及其制备方法 |
-
2017
- 2017-07-28 CN CN201710627454.5A patent/CN107432478A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105011153A (zh) * | 2015-06-19 | 2015-11-04 | 北京元莱健康管理有限公司 | 一种促进儿童眼脑发育缓解视疲劳的组合物及其制备方法 |
| CN106617075A (zh) * | 2017-01-18 | 2017-05-10 | 济南善恩医药科技有限公司 | 一种复合亚麻籽油微囊粉及其制备方法 |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108477622A (zh) * | 2018-04-16 | 2018-09-04 | 赵成群 | 一种婴幼儿全功能营养组合物 |
| CN108968072A (zh) * | 2018-10-13 | 2018-12-11 | 王井中 | 亚麻酸微囊粉及其制备方法和使用方法 |
| CN115252675A (zh) * | 2022-05-23 | 2022-11-01 | 南京联智医药科技有限公司 | 犬用美毛护肤软咀嚼片剂及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106072573A (zh) | 一种适用于老年肌肉衰减症食用的特膳食品 | |
| CN112772813A (zh) | 一种提高免疫力缓解疲劳的复合肽固体饮料及其制备方法 | |
| CN107136511A (zh) | 一种促进脑神经发育的牡丹籽油组合物、牡丹籽油软胶囊及其制备方法 | |
| CN106107463A (zh) | 超级藜麦抗疲劳奶茶制作工艺 | |
| CN107432478A (zh) | 一种复合亚麻籽油微囊粉及其制备方法 | |
| CN102511861A (zh) | 一种添加低聚糖的红枣浓浆 | |
| CN102511864B (zh) | 一种红枣浓浆 | |
| CN106617075A (zh) | 一种复合亚麻籽油微囊粉及其制备方法 | |
| CN105595338A (zh) | 一种适用于糖尿病的特殊医学用途配方食品及其制备方法 | |
| CN107373487A (zh) | 一种甘氨酸亚铁冲剂 | |
| CN104920753A (zh) | 中药压片糖果及其制备方法 | |
| CN103610057A (zh) | 一种提神健脑的含片 | |
| CN107712909A (zh) | 一种铁锌多维口服液 | |
| US20130064924A1 (en) | Nutritional supplement for use under physiologically stressful conditions | |
| CN102511858A (zh) | 一种适合孕妇食用的红枣浓浆及其生产工艺 | |
| CN101129406A (zh) | 复方阿胶系列产品的配方和制造方法 | |
| CN102511860B (zh) | 一种添加植物甾醇适合孕妇食用的红枣浓浆 | |
| CN106035686A (zh) | 超级藜麦养生植物奶 | |
| KR20120119686A (ko) | Ｌ-아르기닌, 비타민ｃ, 비타민 ｂ군, 비타민ａ, 비타민ｅ 및 요오드화칼륨을 주성분으로 함유하는 기능성 음료조성물 | |
| CN102511859A (zh) | 一种添加dha适合孕妇乳母食用的红枣浓浆 | |
| CN107259530A (zh) | 一种用于安神、改善睡眠的百香果配方食品 | |
| TW202302120A (zh) | 腦心血管保健之營養品 | |
| CN101507488A (zh) | 复合强化营养鸡精 | |
| CN1323596C (zh) | 一种微米糖参珍琥王降糖安神夜豆奶片制备方法 | |
| CN1692777A (zh) | 一种微米糖参银耳养颜润肺降糖奶片制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20201215 Address after: Room 103, building 1, Mohai Industrial Park, No. 4, Taixing West Street, Jiyang District, Jinan City, Shandong Province Applicant after: SHANDONG RUIAN PHARMACEUTICAL Co.,Ltd. Address before: Room 2202, building a3-5, Hanyu Jingu, high tech Zone, Jinan City, Shandong Province Applicant before: SHANDONG GRANTHEAL BIOTECHNOLOGY Co.,Ltd. |
|
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20171205 |